SESSION CANCELLED

Pharmacy Grand Rounds

Looking at Alternative Anticoagulation for Left Atrial Appendage (LAA) Thrombi and Closure

• ACPE Universal Activity Number (UAN): JA0000238-0000-20-028-L01-P
• Session Type: Knowledge-based
• CE Credits: A maximum of 0.75 contact hour (0.075 CEU) for the following: 
  • AAPA Category 1 CME Credits
  • ACPE
  • AMA PRA Category 1 Credits™
  • ANCC

• Session Fee: Free for Mayo Clinic staff

SESSION LOCATIONS

Live Session: (11:00am - 11:45am CST)

Until future notice, learners must watch Pharmacy Grand Rounds live via the web by going to the Video Exchange and selecting “Pharmacy Grand Rounds” in the “Streaming Now” section.

Participants may attend by viewing: Live Webcast
Video Recording - access two weeks after session date

COURSE DESCRIPTION

Direct acting oral anticoagulants (DOACs) are increasingly utilized over warfarin to prevent stroke in patients with atrial fibrillation. This practice is reflected by current guidelines, which recommend DOACs as first-line anticoagulation. However, in patients with established left atrial appendage thrombus, warfarin remains the standard of care. This presentation will review the available literature highlighting the potential role of DOACs in patients with left atrial appendage thrombus. Finally, this presentation will explore the role of periprocedural DOACs in patients who have undergone LAA closure.

At the conclusion of this knowledge-based CE session, participants should be able to:

1. Describe the available literature on DOAC use compared to warfarin in patients with nonvalvular atrial fibrillation and LAA thrombi
2. Explain efficacy and safety considerations in selecting and dosing DOACs for the treatment of LAA thrombus
3. Identify patients who may benefit from LAA closure and the role of periprocedural DOACs

Session Announcement

FACULTY INFORMATION

Mikhaila L. Rice, PharmD
PGY1 Pharmacy Resident
Mayo Clinic Hospital - Rochester, MN

Mikhaila received a Doctor of Pharmacy degree from the University of Pittsburgh School of Pharmacy in Pittsburgh, PA.  She is a current PGY1 Pharmacy Resident at Mayo Clinic Hospital - Rochester with practice interests in hematology, oncology, immunology, and infectious disease.

DISCLOSURE STATEMENTS

As a provider accredited by Joint Accreditation Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science (Mayo Clinic School of CPD) must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of these relevant financial relationships will be published in activity materials so those participants in the activity may formulate their own judgments regarding the presentation.

Listed below are individuals with control of the content of this program:

The faculty report the following relationships:

• Mikhaila L. Rice, PharmD
  • Declares no financial relationships pertinent to this session
  • Declares off-label use of devices and medications will be discussed during this presentation, including:
    • Apixiban
    • Dabigatran
    • Edoxaban
    • Rivaroxaban

Course Director and Planning Committee Members declare no relevant financial relationship(s) pertinent to this session.  Members include:

• Brenda Amaris
• Mary Ellen Cordes, MS, APRN, CNC, NE-BC
• Michael Huckabee, MPAS, PA-C, PhD
• Wayne (Nick) Nicholson, MD, PharmD, BCPS
• Garrett Schramm, PharmD, BCPS
• Lee Skrupky, PharmD, BCPS